We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CAP Cells Suitable for Commercial Vaccine Production?

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CAP Cells Suitable for Commercial Vaccine Production?"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
CEVEC Pharmaceuticals, the developer of the potent protein expression system based on human CAP cells, has announced that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

The data were obtained in a collaborative project with Prof. Dr. Reichl at the Max-Planck-Institute for Dynamics of Complex Technical Systems in Magdeburg, an internationally renowned expert for design and optimization of vaccine production processes in Germany.

CAP cells were infected with various human, equine and swine influenza strains and the virus titers compared to MDCK suspension cells.

“CAP cells could prove to be of significant advantage for the production of flu vaccines,” said Dr. Rainer Lichtenberger, CEO of CEVEC. “The achieved virus yields give hope for a more efficient production than with the help of conventional egg-based technology.”

“The infected CAP cells grow rapidly in serum-free and commercially available media. With an optimized medium even higher virus titers can be expected,” added Wolfgang Kintzel, CEVEC’s Chief Commercial Officer and Managing Director.

"The human suspension cell line CAP has an enormous potential for establishment of state-of-the-art influenza vaccine manufacturing processes," said Prof. Reichl from the Max-Planck Insitute in Magdeburg.